Local and peripheral aromatase and breast cancer
Control of aromatase activity in breast cancer cells: The role of cytokines and growth factors

https://doi.org/10.1016/0960-0760(93)90264-WGet rights and content

Abstract

The aromatase complex has a key role in regulating oestrogen formation in normal and malignant breast tissues. Using dexamethasone-treated fibroblasts, derived from breast tumours, breast tumour cytosol and breast tumour-derived conditioned medium (CM) markedly stimulate aromatase activity. The cytokine, interleukin-6 (IL-6) has been identified as a factor present in CM which is capable of stimulating aromatase activity. To examine whether IL-6 may have a role in vivo in regulating breast tissue aromatase activity, IL-6 production and aromatase activity in breast tumour and adipose tissue from breast quadrants were examined. In 56 breasts examined so far, aromatase activity was highest in adipose tissue in the breast quadrant containing the tumour or on which the tumour impinged. There was a significant correlation (P < 0.05, Kendall's rank correlation) between IL-6 production and aromatase activity in these breast tissues. It is concluded that IL-6 may have an important role in regulating aromatase activity in breast tissues.

References (33)

  • P.K. Siiteri et al.

    Role of extraglandular estrogen in human endocrinology

  • W.R. Miller et al.

    Oestradiol synthesis from C19 steroids by human breast cancer

    Br. J. Cancer

    (1974)
  • M.J. Reed et al.

    In situ oestrone synthesis in normal breast and breast tumour tissues: effect of treatment with 4-hydroxyandrostenedione

    Int. J. Cancer

    (1989)
  • M.J. Reed et al.

    Concentrations of oestrone and 4-hydroxyandrostenedione in malignant and normal breast tissues

    Int. J. Cancer

    (1991)
  • W.R. Miller et al.

    The importance of local synthesis of estrogen within the breast

    Steroids

    (1987)
  • M.J. Reed et al.

    Regulation of steroid synthesis and metabolism by growth factors

    Clin. Endocr.

    (1989)
  • Cited by (117)

    • Central aromatization: A dramatic and responsive defense against threat and trauma to the vertebrate brain

      2020, Frontiers in Neuroendocrinology
      Citation Excerpt :

      PGE2 has a high affinity for four known E-prostanoid (EP) receptors: EP 1–4 (Singh et al., 1997). Binding of PGE2 to these receptors can regulate aromatase and E2 via modulation of downstream signaling pathways in other systems (Duncan and Saldanha, 2011; Phillips et al., 1978; Reed et al., 1993). Surprisingly, EP-1 and EP-2 receptors were not represented in the zebra finch genome, however they may play a greater role in non-avian species for the purpose of this review we are going to focus on EP-3 and EP-4 (Warren et al., 2010).

    • Induction of Estrogen Response Following Injury

      2015, Estrogen Effects on Traumatic Brain Injury: Mechanisms of Neuroprotection and Repair
    • Traumatized and inflamed - But resilient: Glial aromatization and the avian brain

      2013, Hormones and Behavior
      Citation Excerpt :

      The hypothesis that an alternate promoter may be responsible for the induction of glial aromatase led us to identify factors associated with neurotrauma that are also known to activate aromatase promoters. Cytokines, a major class of signals up-regulated by traumatic brain injury regulate aromatase gene expression via alternate promoters in normal and malignant breast tissue (Purohit et al., 1995, 2005; Reed et al., 1993; Singh et al., 1997) and microinjections of cytokines into a rat stab wound significantly increase gliosis (Ghirnikar et al., 1998). We therefore reasoned, that cytokine expression may be associated with the up-regulation of glial aromatase in the songbird brain.

    • Aromatase, breast cancer and obesity: A complex interaction

      2012, Trends in Endocrinology and Metabolism
      Citation Excerpt :

      These groups demonstrated significantly elevated levels of estrone, estrone sulfate and estradiol in breast tumor tissue compared with circulating levels [52–54]. Several groups consistently found increased aromatase enzyme activity and mRNA levels in breast fat adjacent to the cancer tissue compared with distal fat or disease-free breast adipose tissue [17,21,45,46,55–57]. In vivo evidence from a transgenic mouse model revealed that aromatase overexpression in breast tissue was sufficient for maintaining hyperplasia in the absence of circulating estrogen and that aromatase inhibitors abrogated hyperplasia [58].

    • Molecular endocrinology and breast cancer - A reed before the wind lives on (a tribute to Professor Mike Reed)

      2011, Steroids
      Citation Excerpt :

      Papers were published on plasma levels of oestrogen in women with and without breast cancer [13], endogenous oestrogen production and metabolism in women with breast or endometrial cancer [14,15], and metabolic clearance rates of oestrogen [14]. A logical extension was to elucidate the role of growth factors and cytokines in the regulation of key enzymes of steroid metabolic pathways [16–20]. More recently Mike became involved in the development of enzyme inhibitors and exploring endocrine-cytotoxic therapy for cancers [21–24].

    • Aromatase and COX in breast cancer: Enzyme inhibitors and beyond

      2007, Journal of Steroid Biochemistry and Molecular Biology
    View all citing articles on Scopus

    Proceedings of the Third International Aromatase Conference.Basic and Clinical Aspects of Aromatase, Bologna, Italy, 14–17 June 1992.

    View full text